RAFFA WEALTH MANAGEMENT, LLC’s Oruka Therapeutics ORKA Stock Holding History

RAFFA WEALTH MANAGEMENT, LLC’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1	Closed	-$63	–	734
2018 Q1	$63	Hold	1	–	–	﹤0.01%	708
2017 Q4	$170	Hold	1	–	–	﹤0.01%	256
2017 Q3	$145	Hold	1	–	–	﹤0.01%	277
2017 Q2	$302	Hold	1	–	–	﹤0.01%	395
2017 Q1	$321	Hold	1	–	–	﹤0.01%	371
2016 Q4	$570	Hold	1	–	–	﹤0.01%	694
2016 Q3	$566	Hold	1	–	–	﹤0.01%	672
2016 Q2	$580	Hold	1	–	–	﹤0.01%	612
2016 Q1	$694	Hold	1	–	–	﹤0.01%	534
2015 Q4	$930	Hold	1	–	–	﹤0.01%	409
2015 Q3	$992	Hold	1	–	–	﹤0.01%	388
2015 Q2	$1.61K	Hold	1	–	–	﹤0.01%	301
2015 Q1	$1.11K	Hold	1	–	–	﹤0.01%	363
2014 Q4	$1.33K	Hold	1	–	–	﹤0.01%	300
2014 Q3	$1.74K	Hold	1	–	–	﹤0.01%	265
2014 Q2	$2.04K	Hold	1	–	–	﹤0.01%	215
2014 Q1	$2.61K	Hold	1	–	–	﹤0.01%	204
2013 Q4	$1.33K	Buy	+1	New	+$2.31K	﹤0.01%	300

Other funds holding ORKA

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

ACP

Aveo Capital Partners Englewood, Colorado $601M AUM 5.92% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RAFFA WEALTH MANAGEMENT, LLC's ORKA Position: Q2 2018 in Review

RAFFA WEALTH MANAGEMENT, LLC sold out of Oruka Therapeutics (ORKA) in Q2 2018, closing a stake of 1 share — an estimated $63 sold.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in ORKA in Q4 2013 and held it in 18 quarters. The position peaked at $2.61K in Q1 2014. 15 funds tracked by Wall St. Rank hold ORKA as of Q2 2018.

RAFFA WEALTH MANAGEMENT, LLC reported no remaining Oruka Therapeutics position as of Q2 2018 after selling out during the quarter.
RAFFA WEALTH MANAGEMENT, LLC sold 1 Oruka Therapeutics share in Q2 2018, an estimated $63.
RAFFA WEALTH MANAGEMENT, LLC first reported a position in Oruka Therapeutics in Q4 2013 and held it in 18 quarters.
RAFFA WEALTH MANAGEMENT, LLC's Oruka Therapeutics position peaked at $2.61K in Q1 2014.
15 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2018.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2018, filed 27 Jul 2026.